UK-based clinical testing programme for somatic and germline BRCA1/2, ATM and CDK12 mutations in prostate cancer: first results

UK-based clinical testing programme for somatic and germline BRCA1/2, ATM and CDK12 mutations in prostate cancer: first results

Objective Germline BRCA2 pathogenic variants (PVs) are known to cause ~4% of prostate cancer, but other homologous repair genes, BRCA1, ATM, PALB2 and Lynch syndrome genes are also involved. Our objective was to assess the contribution of germline and somatic gene variants to prostate cancer.Methods...

Full description

Saved in:
Bibliographic Details
Main Authors: Helene Schlecht, Emma R Woodward, D Gareth Evans, Fiona Lalloo, George Burghel, Ashwin Sachdeva, Andrew Hudson, Robert Bristow, Omi Parikh
Format: Article
Language:English
Published: BMJ Publishing Group 2025-02-01
Series:BMJ Oncology
Online Access:https://bmjoncology.bmj.com/content/4/1/e000592.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items